Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 89, Issue 2, Pages S29-S32Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2023.05.049
Keywords
alopecia; alopecia areata; alopecia totalis; alopecia universalis; baricitinib; deuruxolitinib; hair loss; JAK; JAK inhibitor; Janus kinase; Janus kinase inhibitor; ritlecitinib; ruxolitinib; tofacitinib
Categories
Ask authors/readers for more resources
JAK inhibitors have revolutionized the treatment of alopecia areata (AA), making it possible to treat moderate-to-severe cases that were previously refractory. This article provides a brief overview of the history of and rationale for JAK inhibitor treatment in AA, discusses phase 3 clinical trial data, and addresses considerations such as differences among JAK inhibitors, safety, and patient selection.
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
